Author: [AUTHOR] Published on 7/28/2023 5:00:00 AM

FDA Office of Translational Sciences Announces Availability of 2022 Annual Report

The US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Translational Sciences (OTS) announces the availability of the 2022 OTS Annual Report.

OTS contributes to CDER’s mission by performing drug regulatory reviews, actively engaging in regulatory science research, and facilitating research activities at CDER to drive innovation and advancements in the science of drug development. The office helps establish technology transfer agreements, supports CDER’s intramural and extramural research programs, and promotes collaborations between CDER scientists and its external stakeholders on topics that advance regulatory decision-making and encourage innovation in the development, manufacture, and safe use of drugs.

The 2022 OTS Annual Report organizes OTS’s achievements by its core activities:

• Drug development and regulatory review
• Science and research
• Inspections
• Knowledge management
• Outreach and communications efforts

To learn more about how OTS supports advancements in human health through scientific and regulatory innovation, please visit 2022 OTS Annual Report.

---

The Office of Clinical Pharmacology (OCP) is pleased to offer the e-mail subscription service Clinical Pharmacology Corner. This is a free service from FDA to provide occasional updates from OCP regarding newly approved therapies, new regulatory and scholarly publications, upcoming events and other items of interest. Subscribe today or click the button below select Clinical Pharmacology Corner under Drugs.

We always welcome your thoughts regarding the format, content, and utility of this communication. Comments may be sent via email to ocp@fda.hhs.gov.

This communication was prepared by Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.

Subscribe Now